Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00108498 · ClinicalTrials.gov registry record · Phase 1
New Pharmacological Treatment for Obstructive Sleep Apnea
A Phase 1 study of Obstructive Sleep Apnea, sponsored by US Department of Veterans Affairs.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Study location
NCT00108498 is a Phase 1 study of Obstructive Sleep Apnea that has completed, run by US Department of Veterans Affairs. The trial reports 1 study location across 1 state.
The verdict
NCT00108498, a Phase 1 study of Obstructive Sleep Apnea, has completed, sponsored by US Department of Veterans Affairs.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1
- Study location
Study Summary
This study will determine if mirtazapine, a unique antidepressant that does not disturb sleep, will improve obstructive sleep apnea (OSA). The design is randomized, crossover, double blind, and placebo controlled. On two consecutive nights of one week, the patients receive either 30 mg mirtazapine or placebo at bedtime. The following week, the alternative medication is administered. The patients have known mild to moderate sleep apnea. The endpoints of the study are the apnea + hypopnea index (AHI), sleep quality, and the degree of arterial oxygen desaturation.
Conditions Studied
Interventions
- DRUG mirtazapine
Study Locations (1)
Florida
- Malcom Randall VAMC - Gainesville
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-10 |
| Est. Completion | 2007-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00108498
The ClinicalTrials.gov registry entry for NCT00108498 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is US Department of Veterans Affairs, which has 632 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obstructive Sleep Apnea appearing as the primary indexed condition, and to 1 intervention - of which mirtazapine is the first listed.
NCT00108498 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT00108498 about?
NCT00108498 is a clinical study titled "New Pharmacological Treatment for Obstructive Sleep Apnea". This study will determine if mirtazapine, a unique antidepressant that does not disturb sleep, will improve obstructive sleep apnea (OSA). The design is randomized, crossover, double blind, and placebo controlled. On two consecutive nights of one week, the patients receive either 30 mg mirtazapine o...
What is the current status of trial NCT00108498?
This trial is currently completed. It is a Phase 1 study. The study started on 2003-10. Estimated completion is 2007-03.
What conditions does trial NCT00108498 study?
This clinical trial studies the following conditions: Obstructive Sleep Apnea.
What interventions are being tested in trial NCT00108498?
The interventions under investigation include: mirtazapine (DRUG).
Who is sponsoring clinical trial NCT00108498?
This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00108498 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obstructive Sleep Apnea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Intermittent Hypoxia-initiated Plasticity in Humans: A Multi-pronged Therapeutic Approach to Treat Sleep Apnea and Overlapping Co-morbidities
RECRUITING · Phase 1
-
DRonabinol Treatment of OSA
RECRUITING · Phase 1
-
Trazodone on OSA Endotypes
RECRUITING · Phase 1
-
Atomoxetine and DAW2022 on OSA Severity
RECRUITING · Phase 1
-
Is Obstructive Sleep Apnea Important in the Development of Alzheimer's Disease?
RECRUITING · Phase 1
-
Rescue Pharmacotherapy for OSA
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.